Shares of Celyad SA (NASDAQ:CYAD) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Analysts have set a 12 month consensus target price of $74.00 for the company, according to Zacks. Zacks has also assigned Celyad an industry rank of 192 out of 265 based on the ratings given to its competitors.
Several research analysts have recently weighed in on CYAD shares. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $74.00 target price on shares of Celyad in a research note on Monday, October 9th. ValuEngine downgraded Celyad from a “hold” rating to a “sell” rating in a research note on Friday, December 1st.
Shares of Celyad (NASDAQ CYAD) traded down $2.30 during mid-day trading on Thursday, hitting $44.58. The stock had a trading volume of 5,209 shares, compared to its average volume of 5,896. Celyad has a twelve month low of $19.57 and a twelve month high of $64.75.
COPYRIGHT VIOLATION WARNING: “Celyad SA (CYAD) Receives Consensus Recommendation of “Strong Buy” from Analysts” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/02/01/celyad-sa-cyad-receives-consensus-recommendation-of-strong-buy-from-analysts.html.
Celyad Company Profile
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celyad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad and related companies with MarketBeat.com's FREE daily email newsletter.